Duligotuzumab

Duligotuzumab is a monoclonal antibody designed for the treatment of cancer. This drug was developed by Merck KGaA and ImClone Systems.

Mechanism of Action

Duligotuzumab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2). By binding to these receptors, duligotuzumab inhibits the growth and proliferation of cancer cells that overexpress these receptors.

Clinical Trials

Duligotuzumab has been studied in clinical trials for the treatment of various types of cancer, including head and neck cancer, colorectal cancer, and non-small cell lung cancer. However, the results of these trials have been mixed, and the drug is not currently approved for use in any country.

Side Effects

Like all drugs, duligotuzumab can cause side effects. The most common side effects reported in clinical trials include fatigue, nausea, diarrhea, and skin rash. In some cases, these side effects can be severe and may require medical attention.

See Also

• Monoclonal antibodies
• Epidermal growth factor receptor
• Human epidermal growth factor receptor 2
• Cancer treatment

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia